Thermo Fisher Scientific Inc. (TMO)

230.00
NYSE : Health Technology
Prev Close 230.79
Day Low/High 229.89 / 232.80
52 Wk Low/High 172.15 / 236.29
Avg Volume 1.32M
Exchange NYSE
Shares Outstanding 402.80M
Market Cap 92.96B
EPS 5.60
P/E Ratio 38.98
Div & Yield 0.68 (0.28%)

Latest News

Thermo Fisher Scientific Reports Second Quarter 2018 Results

Thermo Fisher Scientific Reports Second Quarter 2018 Results

WALTHAM, Mass., July 25, 2018 /PRNewswire/ -- Thermo Fisher Scientific Inc.

Jim's Daily Rundown

Jim discusses his interview with Larry Kudlow at the Delivering Alpha conference, Nucor's earnings, Danaher's earnings and announced spin, Abbott Labs, and Comcast!

Thermo Fisher Scientific Declares Quarterly Dividend

Thermo Fisher Scientific Declares Quarterly Dividend

WALTHAM, Mass., July 13, 2018 /PRNewswire/ -- Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Signs Agreement To Acquire Gatan From Roper Technologies

Thermo Fisher Scientific Signs Agreement To Acquire Gatan From Roper Technologies

WALTHAM, Mass. and SARASOTA, Fla.

Facebook, General Electric and General Mills - 5 Things You Must Know

Facebook, General Electric and General Mills - 5 Things You Must Know

U.S. stock futures are lower with trade war concerns and support for tighter investment rules by U.S. lawmakers holding down markets; Facebook plans to reverse a ban on cryptocurrency ads; General Mills and Rite Aid report earnings.

Healthcare Heavyweights Weigh M&A After GE Spin-off - ICYMI

Healthcare Heavyweights Weigh M&A After GE Spin-off - ICYMI

Here's what you need to know now for Tuesday, June 26.

GE Healthcare Spinoff Prompts Split Views on M&A Effect

GE Healthcare Spinoff Prompts Split Views on M&A Effect

A 'major M&A chip is now off the table most likely,' Evercore ISI analysts say, but Needham says more med tech deals are possible over the longer term.

Thermo Fisher Scientific To Hold Earnings Conference Call On Wednesday, July 25, 2018

Thermo Fisher Scientific To Hold Earnings Conference Call On Wednesday, July 25, 2018

WALTHAM, Mass. , June 26, 2018 /PRNewswire/ -- Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Shows Newest Mass Spectrometry Innovations At ASMS 2018

Thermo Fisher Scientific Shows Newest Mass Spectrometry Innovations At ASMS 2018

SAN DIEGO, June 4, 2018 /PRNewswire/ --  ASMS 2018 - Thermo Fisher Scientific Inc.

Jim Cramer: Stocks That Do Well In a Declining Rate Environment Are Back

Jim Cramer: Stocks That Do Well In a Declining Rate Environment Are Back

The crash of oil will only accelerate the move.

Berkshire Hathaway, Align Technology, Seaspan: 'Mad Money' Lightning Round

Berkshire Hathaway, Align Technology, Seaspan: 'Mad Money' Lightning Round

Jim Cramer focuses on Berkshire Hathaway, Align Technology, Seaspan, Criticare Systems, CoreSite Realty, Hi-Crush Partners and more.

Is This Rally for Real?: Cramer's 'Mad Money' Recap (Monday 5/14/18)

Is This Rally for Real?: Cramer's 'Mad Money' Recap (Monday 5/14/18)

Jim Cramer asks, why is there such a double-standard? Why do selloffs have instant credibility and advances are to be doubted?

The New #234 Most Shorted S&P 500 Component: Thermo Fisher Scientific

The most recent short interest data has been released for the 04/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

An Oversold Rally Has Finally Arrived, But We'll Be Overbought Soon

I also expect the VIX to rise by mid-May.

Jim Cramer: Follow the Bouncing Equities

Jim Cramer: Follow the Bouncing Equities

Markets start day with a bungee jump.

Uncertainty Is the New Market Normal -- And More Severe Tests Are Coming

Uncertainty Is the New Market Normal -- And More Severe Tests Are Coming

There is likely more headline risk to our front than to our rear.

Nike, Zebra Technologies, Blackstone: 'Mad Money' Lightning Round

Nike, Zebra Technologies, Blackstone: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Nike, Zebra Technologies, Blackstone, Ingersoll-Rand, Thermo Fisher Scientific and more.

Trade Barriers and Interest Rates: Cramer's 'Mad Money' Recap (Monday 4/23/18)

Trade Barriers and Interest Rates: Cramer's 'Mad Money' Recap (Monday 4/23/18)

Jim Cramer considers which is worse for stocks: the 10-year Treasury breaching 3% or the tariff battles with China.

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Washington receded and earnings came to the fore, but we're still seeing insane values and some surprises, says Jim Cramer.

Rapid Mycoplasma Testing Method Now Accepted By Regulators For QA/QC And Lot Release

Rapid Mycoplasma Testing Method Now Accepted By Regulators For QA/QC And Lot Release

MycoSEQ Mycoplasma Detection Method can accelerate production timelines for manufacturers of cell and gene therapies, biotherapeutics, vaccines and other cell-culture-based modalities

Rapid Mycoplasma Testing Method Now Accepted By Regulators For QA/QC And Lot Release

Rapid Mycoplasma Testing Method Now Accepted By Regulators For QA/QC And Lot Release

MycoSEQ Mycoplasma Detection Method can accelerate production timelines for manufacturers of cell and gene therapies, biotherapeutics, vaccines and other cell-culture-based modalities

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

In a special edition of Mad money, Jim Cramer examines this brutal decline and lays out the game plan for next week -- live from Minneapolis ahead of the Super Bowl.

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Jim Cramer highlights Shopify, Kinder Morgan, Thermo Fisher Scientific, Radius Health, Merck, Pfizer and more.

TheStreet Quant Rating: A+ (Buy)